Cargando…
Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
Dipeptidyl peptidase (DPP)-4, a molecular target of DPP-4 inhibitors, which are type 2 diabetes drugs, is expressed in a variety of cell types, tissues and organs. DPP-4 has been shown to be involved in cancer biology, and we have recently shown that a DPP-4 inhibitor promoted the epithelial mesench...
Autores principales: | Li, Shaolan, Fan, Yang, Kumagai, Asako, Kawakita, Emi, Kitada, Munehiro, Kanasaki, Keizo, Koya, Daisuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037814/ https://www.ncbi.nlm.nih.gov/pubmed/31991851 http://dx.doi.org/10.3390/ijms21030805 |
Ejemplares similares
-
Inhibition of Dipeptidyl Peptidase-4 Activates Autophagy to Promote Survival of Breast Cancer Cells via the mTOR/HIF-1α Pathway
por: Kawakita, Emi, et al.
Publicado: (2023) -
Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice
por: Takagaki, Yuta, et al.
Publicado: (2019) -
Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016) -
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018) -
Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)